Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, January 2009, p. 277-280, Vol. 53, No. 1
0066-4804/09/$08.00+0 doi:10.1128/AAC.00912-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
Relative Strengths of the Class 1 Integron Promoter Hybrid 2 and the Combinations of Strong and Hybrid 1 with an Active P2 Promoter
Costas C. Papagiannitsis,1
Leonidas S. Tzouvelekis,2 and
Vivi Miriagou1*
Laboratory of Bacteriology, Hellenic Pasteur Institute,1
Department of Microbiology, Medical School, University of Athens, Athens, Greece2
Received 10 July 2008/
Returned for modification 23 August 2008/
Accepted 2 November 2008

ABSTRACT
The relative strengths of the uncommon promoters hybrid 2, hybrid
1 with an active P2 promoter (hybrid 1+P2), and strong+P2, which
drive transcription of resistance genes in class 1 integrons,
were evaluated using
blaGES-1 as a reporter gene cassette. Hybrid
2 was stronger than hybrid 1. Coupling P2 with the strong promoter
and with hybrid 1 caused a measurable increase in GES-1 expression.

INTRODUCTION
Expression of antibiotic resistance genes in the variable region
of class 1 integrons is driven by a promoter (Pc) that is 214
bases from the inner boundary of the 5' conserved segment and
located within the coding sequence of
intI1. There are four
versions of Pc, designated "weak," "strong," "hybrid 1," and
"hybrid 2," exhibiting differences in the –35 and/or –10
sequences, separated by 17 bases. Additionally, a second promoter,
P2, complements the Pc weak promoter in various integrons. P2
occurs 119 bases downstream from Pc and is formed by an insertion
of three G bases optimizing the spacing (17 bases) between the
–35 and –10 hexamers (P2 active) (
5). The relative
strengths of the weak, strong, and hybrid 1 versions of the
Pc promoter, as well as that of the weak promoter complemented
by P2 (weak+P2), have been determined previously (
5,
9), while
that of hybrid 2, which occurs in a relatively small number
of class 1 integrons (Table
1) (
3,
4,
6,
8,
10,
14,
16), has
not been studied. The increasing number of characterized integrons
revealed the existence of additional promoter sequences, such
as the combinations of the strong promoter and hybrid 1 with
P2 (Table
1) (
7,
12). In this study, we evaluated the relative
strengths of hybrid 2 and the latter promoter combinations introduced
into a GES-1 extended-spectrum-β-lactamase-encoding integron.
Comparative assessments included amounts of
blaGES-1 transcripts,
levels of hydrolytic activity of GES-1, and MICs of β-lactams.
View this table:
[in this window]
[in a new window]
|
TABLE 1. Characteristics of class 1 integrons with the uncommon promoter sequence Pc hybrid 2 and the combinations of P2 with Pc hybrid 1 and Pc strong
|

Cloning of a GES-1-encoding integron and construction of the Pc-P2 sequence variants.
A GES-1-producing isolate of
Pseudomonas aeruginosa (Pa-G1)
was used as a source of In58-G1, a typical class 1 integron
with a weak promoter containing a single gene cassette,
blaGES-1 (GenBank accession no. EU598463). A 1,641-bp fragment of In58-G1,
including the
blaGES-1 cassette and the promoter sequence, was
amplified by PCR and cloned into the Topo TA vector (Invitrogen,
Carlsbad, CA), yielding plasmid pTOPO-G1. An EcoRI fragment
of 1,690 bp from pTOPO-G1 was treated with a DNA polymerase
Klenow fragment and introduced into the single HincII site of
plasmid pACYC177, thereby disrupting the resident
blaTEM-1.
A recombinant plasmid of 5,607 bp (pHP327) carrying the 1,641-bp
segment of In58-G1 in an orientation opposite that of the 246-bp
5' remnant of
blaTEM-1 was selected for the construction of
the various Pc-P2 sequence combinations. Site-specific mutagenesis
was performed using 10 mutagenic primers (Table
2) and a QuickChange
site-directed mutagenesis kit (Stratagene, La Jolla, CA). Seven
variants of plasmid pHP327 carrying the weak, strong, hybrid
1, hybrid 2, weak+P2, strong+P2, and hybrid 1+P2 promoter sequences
were studied. Additionally, a pHP327 variant with a promoterless
integron was constructed by reverting the 29-bp Pc sequence
and also deleting 5 of the 17 bp between the –35 and –10
hexamers. Entire plasmid sequences were verified on both strands
by use of an API377 sequencer (Applied Biosystems, Foster City,
CA).
Escherichia coli MC4100, a
ampC mutant, was used as a host.
Isoelectric focusing and staining with nitrocefin showed that
GES-1, with a pI of 5.8, was the sole β-lactamase produced
by the respective clones.

Characterization of blaGES-1 transcripts by Northern hybridization and real-time reverse transcription-PCR (RT-PCR).
Total RNA was prepared using RNA protect and RNeasy mini kits
(Qiagen, Hilden, Germany). RNA samples (10 µg from each
strain) were electrophoresed through formaldehyde-containing
agarose, transferred to Hybond-N
+ membranes (Amersham Biosciences,
United Kingdom), and hybridized with a digoxigenin-labeled
blaGES-1-specific
probe (618 bp, nucleotides [nt] 744 to 1361; GenBank accession
no. EU598463) following standard techniques (
15). These experiments
confirmed production of similarly sized
blaGES-1 transcripts
(approximately 1.2 kb) in all seven strains and also indicated
higher transcription levels in the strains carrying the Pc strong
sequence (data not shown).
RNA samples were treated with RNase-free DNase I using a Turbo DNA-free kit (Ambion Inc., Foster City, CA). Real-time RT-PCR was performed using a Quantifast Sybr green RT-PCR kit (Qiagen). Three reactions per sample were performed, using 10, 20, and 50 ng of total RNA. Each reaction mixture also contained Quantifast SYBR green RT-PCR master mix (12.5 µl), Quantifast RT mix (0.25 µl), and 500 nM of each oligonucleotide primer (Ven-8P and Ven-12 [Table 2]) in a final volume of 25 µl. The pACYC177 resident gene aphA1 was used as a reference. The respective reactions were carried out as described above with primers Aph-F and Aph-R (Table 2). RT was carried out for 10 min at 50°C and terminated by heating at 95°C for 5 min. A two-step cycling PCR was then performed for 40 cycles, with a denaturation step at 95°C for 10 s and an annealing-extension step at 60°C for 30 s. All reactions were carried out in triplicate using a Corbett Rotor-Gene 6000 (Corbett Life Science, Sydney, Australia). Rotor-Gene 6000 software (version 1.7) was used for data analysis. Quantities of blaGES-1 and aphA1 in the same sample were expressed in threshold cycle values. The target-reference ratios were calculated, and the normalized values were used to compare differential blaGES-1 expression levels. The relative amounts of blaGES-1 transcripts under the control of the seven promoter sequences are presented in Table 3. The lowest value, observed for the weak promoter, was set to 1. Differences in strength among the weak, strong, hybrid 1, and weak+P2 promoters were generally in line with those reported previously (9). The strong promoter appeared to be 17 times more efficient than the weak promoter. The respective increase was lower for the weak+P2 sequence and marginal for hybrid 1 (4.7- and 1.9-fold, respectively). Association of P2 with hybrid 1 caused a 3.5-fold increase in the amount of blaGES-1 transcript, while the respective increase in the strength of the strong sequence was minor. The efficiency of hybrid 2 was comparable to that of the weak+P2 combination and approximately 2.5-fold higher than that of hybrid 1. blaGES-1 transcripts from the promoterless integron sequence were not detected (Table 3).
View this table:
[in this window]
[in a new window]
|
TABLE 3. Effect of integron promoter sequences on the relative amounts of blaGES-1 transcripts, β-lactamase activities, and β-lactam resistance levels in E. coli MC4100 strains carrying a plasmid-borne blaGES-1 gene cassette
|

β-Lactamase activities and resistance levels to β-lactams.
β-Lactamase-containing extracts were derived by ultrasonic
treatment of bacterial cell suspensions and clarified by ultracentrifugation
(
4). The protein content was measured with a protein assay kit
(Bio-Rad Laboratories, Hercules, CA). β-Lactamase activity
was quantified by spectrophotometry using nitrocefin as a reporter
substrate (

M482 = 17,400 M
–1·cm
–1 [
17]).
Results were expressed as units of activity. One unit was the
amount of enzyme hydrolyzing 1 nmol of substrate/min/mg of protein
at 30°C and pH 7.0. Hydrolytic activities of the extracts
from strains carrying the Pc strong sequences were higher than
those of the strains with the hybrid promoters. The lowest activity
was observed in the strain carrying the weak version of Pc (at
least 26- and 3-fold lower than those of the strains with strong
and hybrid promoters, respectively). The β-lactamase activity
of the strain with hybrid 2 was approximately twofold higher
than that of the hybrid 1-possessing strain. The presence of
a P2 promoter along with the weak and hybrid 1 sequences was
associated with an increase in β-lactamase activity (approximately
6.2- and 3.4-fold, respectively). Also, the hydrolytic activity
of the strain with the strong+P2 combination was slightly higher
than that of the strain carrying the strong promoter (Table
3).
Susceptibilities to ampicillin, piperacillin, cefaclor, cefuroxime, ceftazidime, aztreonam, and cefepime were determined by Etest (AB Biodisk, Solna, Sweden). MIC differences were in line with those of the respective β-lactamase activities. As expected, differences in resistance levels were more pronounced with the narrow-spectrum cephalosporins and ceftazidime, which are GES-1 substrates preferable to piperacillin, cefepime, and aztreonam (11). The higher MICs were seen with the two strains carrying the strong promoter and the lower MICs with the strains with the weak and hybrid 1 promoters. MICs for E. coli strains harboring the plasmids with the hybrid 2, weak+P2, and hybrid 1+P2 sequences did not differ significantly. Resistance levels of the strains carrying strong and strong+P2 sequences were also similar. Most β-lactams tested were more active against the strain with hybrid 1 than against the strain possessing the hybrid 1+P2 combination (Table 3).

Conclusions.
Determination of enzymatic activity and susceptibility testing
have been used for the characterization of the common promoters
of the class 1 integrons (
5,
9). We used here a similar methodology
to study hybrid 2, strong+P2, and hybrid 1+P2. Additionally,
we employed a real-time RT-PCR assay for the relative quantification
of the
blaGES-1 transcripts. Results of the latter method were
in agreement with the quantitative assessment of hydrolytic
activities as well as resistance levels conferred by the indicator
β-lactamase. Additionally, classification of the weak,
strong, hybrid 1, and weak+P2 promoters according to strength
was as published by Lévesque et al. (
9), although the
different expression systems and assays do not allow for a direct
comparison. Nevertheless, the results clearly indicate that
the hybrid 2 version of Pc is an effective promoter similar
in strength to weak+P2 and stronger than hybrid 1. It is also
shown that the active configuration of P2 is functional when
coupled with the strong and hybrid 1 promoters, resulting in
a measurable increase in expression of an immediately downstream
gene cassette. The levels of this increase were comparable in
all three Pc+P2 combinations studied here, suggesting that the
operation of P2 is probably not affected by the type of the
preceding Pc sequence.
Promoter strength is a key factor in determining transcription of resistance gene cassettes in class 1 integrons. Therefore, the evaluation of the strengths of hybrid 2, hybrid 1+P2, and strong+P2 may be useful in explaining resistance phenotypes in strains containing these sequences. Cassette position as well as the sequence of the respective attC site also influences expression in multicassette arrays (5, 13). The potential of a resistance gene cassette to confer a wide range of resistance levels may facilitate establishment of these determinants under various conditions. Also, it may have implications in the phenotypic recognition of microorganisms carrying antibiotic resistance integrons.

ACKNOWLEDGMENTS
This work was supported by the Hellenic Pasteur Institute and
a Kapodistrias grant from the National University of Athens.
We thank Irene Siatravani for technical assistance.

FOOTNOTES
* Corresponding author. Mailing address: Laboratory of Bacteriology, Hellenic Pasteur Institute, Vas. Sofias 127, Athens 11521, Greece. Phone: 30-210-6478810. Fax: 30-210-6423626. E-mail:
miriagou{at}pasteur.gr 
Published ahead of print on 10 November 2008. 

REFERENCES
1 - Reference deleted.
2 - Reference deleted.
3 - Bunny, K. L., R. M. Hall, and H. W. Stokes. 1995. New mobile gene cassettes containing an aminoglycoside resistance gene, aacA7, and a chloramphenicol resistance gene, catB3, in an integron in pBWH301. Antimicrob. Agents Chemother. 39:686-693.[Abstract]
4 - Colinon, C., V. Miriagou, A. Carattoli, F. Luzzaro, and G. M. Rossolini. 2007. Characterization of the IncA/C plasmid pCC416 encoding VIM-4 and CMY-4 β-lactamases. J. Antimicrob. Chemother. 60:258-262.[Abstract/Free Full Text]
5 - Collis, C. M., and R. M. Hall. 1995. Expression of antibiotic resistance genes in the integrated cassettes of integrons. Antimicrob. Agents Chemother. 39:155-162.[Abstract]
6 - Doi, Y., N. Shibata, K. Shibayama, K. Kamachi, H. Kurokawa, K. Yokoyama, T. Yagi, and Y. Arakawa. 2002. Characterization of a novel plasmid-mediated cephalosporinase (CMY-9) and its genetic environment in an Escherichia coli clinical isolate. Antimicrob. Agents Chemother. 46:2427-2434.[Abstract/Free Full Text]
7 - Gonzalez-Zorn, B., A. Catalan, J. A. Escudero, L. Dominguez, T. Teshager., C. Porrero, and M. A. Moreno. 2005. Genetic basis for dissemination of armA. J. Antimicrob. Chemother. 56:583-585.[Abstract/Free Full Text]
8 - Lagatolla, C., E. Edalucci, L. Dolzani, M. L. Riccio, F. De Luca, E. Medessi, G. M. Rossolini, and E. A. Tonin. 2006. Molecular evolution of metallo-β-lactamase-producing Pseudomonas aeruginosa in a nosocomial setting of high-level endemicity. J. Clin. Microbiol. 44:2348-2353.[Abstract/Free Full Text]
9 - Lévesque, C., S. Brassard, J. Lapointe, and P. H. Roy. 1994. Diversity and relative strength of tandem promoters for the antibiotic-resistance genes of several integrons. Gene 142:49-54.[CrossRef][Medline]
10 - Peng, C. F., and S. F. Chang. 1992. Molecular cloning and nucleotide sequencing of a novel aminoglycoside 6'-N-acetyltransferase gene from an R-plasmid of Salmonella typhimurium S24 isolated in Taiwan. Microbiol. Immunol. 36:339-350.[Medline]
11 - Poirel, L., I. Le Thomas, T. Naas, A. Karim, and P. Nordmann. 2000. Biochemical sequence analysis of GES-1, a novel class A extended-spectrum β-lactamase, and the class 1 integron In52 from Klebsiella pneumoniae. Antimicrob. Agents Chemother. 44:622-632.[Abstract/Free Full Text]
12 - Pournaras, S., A. Ikonomidis, L. S. Tzouvelekis, D. Tokatlidou, N. Spanakis, A. N. Maniatis, N. J. Legakis, and A. Tsakris. 2005. VIM-12, a novel plasmid-mediated metallo-β-lactamase from Klebsiella pneumoniae that resembles a VIM-1/VIM-2 hybrid. Antimicrob. Agents Chemother. 49:5153-5156.[Abstract/Free Full Text]
13 - Recchia, G. D., and R. M. Hall. 1995. Gene cassettes: a new class of mobile element. Microbiology 141:3015-3027.[Free Full Text]
14 - Riccio, M. L., L. Pallecchi, R. Fontana, and G. M. Rossolini. 2001. In70 of plasmid pAX22, a blaVIM-1-containing integron carrying a new aminoglycoside phosphotransferase gene cassette. Antimicrob. Agents Chemother. 45:1249-1253.[Abstract/Free Full Text]
15 - Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
16 - Tennstedt, T., R. Szczepanowski, I. Krahn, A. Puhler, and A. Schluter. 2005. Sequence of the 68,869 bp IncP-1
plasmid pTB11 from a waste-water treatment plant reveals a highly conserved backbone, a Tn402-like integron and other transposable elements. Plasmid 53:218-238.[CrossRef][Medline] 17 - Zafaralla, G., E. K. Manavathu, S. A. Lerner, and S. Mobashery. 1992. Elucidation of the role of arginine-244 in the turnover processes of class A β-lactamases. Biochemistry 31:3847-3852.[CrossRef][Medline]
Antimicrobial Agents and Chemotherapy, January 2009, p. 277-280, Vol. 53, No. 1
0066-4804/09/$08.00+0 doi:10.1128/AAC.00912-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.